Cargando…

The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Dyslipidemia, a condition implying high cardiovascular risks, has been widely studied on its potential nutrition interventions, including functional foods. This study aims to examine the effect of nattokinase monascus supplements (NMSs) on cardiovascular biomarkers and carotid intima-media thickness...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoming, Zeng, Xuejiao, Mahe, Jinli, Guo, Kai, He, Panpan, Yang, Qianwen, Zhang, Zhiwei, Li, Zhongxia, Wang, Di, Zhang, Zheqing, Wang, Lei, Jing, Lipeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574353/
https://www.ncbi.nlm.nih.gov/pubmed/37836525
http://dx.doi.org/10.3390/nu15194239
_version_ 1785120674612772864
author Liu, Xiaoming
Zeng, Xuejiao
Mahe, Jinli
Guo, Kai
He, Panpan
Yang, Qianwen
Zhang, Zhiwei
Li, Zhongxia
Wang, Di
Zhang, Zheqing
Wang, Lei
Jing, Lipeng
author_facet Liu, Xiaoming
Zeng, Xuejiao
Mahe, Jinli
Guo, Kai
He, Panpan
Yang, Qianwen
Zhang, Zhiwei
Li, Zhongxia
Wang, Di
Zhang, Zheqing
Wang, Lei
Jing, Lipeng
author_sort Liu, Xiaoming
collection PubMed
description Dyslipidemia, a condition implying high cardiovascular risks, has been widely studied on its potential nutrition interventions, including functional foods. This study aims to examine the effect of nattokinase monascus supplements (NMSs) on cardiovascular biomarkers and carotid intima-media thickness (CIMT) in patients with dyslipidemia. A total of 113 eligible subjects were randomly assigned to receive either NMSs or a placebo (55 and 58, respectively). After a 120-day intervention, there were significant mean absolute changes in total cholesterol (TC), low-density cholesterol (LDL-C), non-high-density cholesterol (non-HDL-C), and low-density cholesterol to high-density cholesterol ratio (LDL-C to HDL-C ratio), with values of −0.52 (95% CI: −0.51 to −0.54) mmol/L, −0.43 (95% CI: −0.45 to −0.41) mmol/L, −0.52 (95% CI: −0.52 to −0.52) mmol/L, and −0.29 (95% CI: −0.30 to −0.28) mmol/L, respectively, between the two groups. However, no significant differences were found in triglycerides (TGs), high-density cholesterol (HDL-C), and CIMT. Furthermore, the results for lipids and CIMT remained essentially unchanged after adjusting for various confounding factors using the analysis of covariance model. There were no significant differences in coagulation, liver function, renal function, or other indicators. No intervention-related adverse events, such as mouth ulcers, drooling, and stomach pain, were reported. The study results demonstrate that NMSs can ameliorate lipid levels (TC, LDL-C, non-HDL-C, and the LDL-C to HDL-C ratio) without the occurrence of adverse events. However, it did not significantly affect serum TG, HDL-C, and CIMT.
format Online
Article
Text
id pubmed-10574353
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105743532023-10-14 The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial Liu, Xiaoming Zeng, Xuejiao Mahe, Jinli Guo, Kai He, Panpan Yang, Qianwen Zhang, Zhiwei Li, Zhongxia Wang, Di Zhang, Zheqing Wang, Lei Jing, Lipeng Nutrients Article Dyslipidemia, a condition implying high cardiovascular risks, has been widely studied on its potential nutrition interventions, including functional foods. This study aims to examine the effect of nattokinase monascus supplements (NMSs) on cardiovascular biomarkers and carotid intima-media thickness (CIMT) in patients with dyslipidemia. A total of 113 eligible subjects were randomly assigned to receive either NMSs or a placebo (55 and 58, respectively). After a 120-day intervention, there were significant mean absolute changes in total cholesterol (TC), low-density cholesterol (LDL-C), non-high-density cholesterol (non-HDL-C), and low-density cholesterol to high-density cholesterol ratio (LDL-C to HDL-C ratio), with values of −0.52 (95% CI: −0.51 to −0.54) mmol/L, −0.43 (95% CI: −0.45 to −0.41) mmol/L, −0.52 (95% CI: −0.52 to −0.52) mmol/L, and −0.29 (95% CI: −0.30 to −0.28) mmol/L, respectively, between the two groups. However, no significant differences were found in triglycerides (TGs), high-density cholesterol (HDL-C), and CIMT. Furthermore, the results for lipids and CIMT remained essentially unchanged after adjusting for various confounding factors using the analysis of covariance model. There were no significant differences in coagulation, liver function, renal function, or other indicators. No intervention-related adverse events, such as mouth ulcers, drooling, and stomach pain, were reported. The study results demonstrate that NMSs can ameliorate lipid levels (TC, LDL-C, non-HDL-C, and the LDL-C to HDL-C ratio) without the occurrence of adverse events. However, it did not significantly affect serum TG, HDL-C, and CIMT. MDPI 2023-09-30 /pmc/articles/PMC10574353/ /pubmed/37836525 http://dx.doi.org/10.3390/nu15194239 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Xiaoming
Zeng, Xuejiao
Mahe, Jinli
Guo, Kai
He, Panpan
Yang, Qianwen
Zhang, Zhiwei
Li, Zhongxia
Wang, Di
Zhang, Zheqing
Wang, Lei
Jing, Lipeng
The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_full The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_fullStr The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_full_unstemmed The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_short The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_sort effect of nattokinase-monascus supplements on dyslipidemia: a four-month randomized, double-blind, placebo-controlled clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574353/
https://www.ncbi.nlm.nih.gov/pubmed/37836525
http://dx.doi.org/10.3390/nu15194239
work_keys_str_mv AT liuxiaoming theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT zengxuejiao theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT mahejinli theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT guokai theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT hepanpan theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT yangqianwen theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT zhangzhiwei theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT lizhongxia theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT wangdi theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT zhangzheqing theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT wanglei theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT jinglipeng theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT liuxiaoming effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT zengxuejiao effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT mahejinli effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT guokai effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT hepanpan effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT yangqianwen effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT zhangzhiwei effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT lizhongxia effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT wangdi effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT zhangzheqing effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT wanglei effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial
AT jinglipeng effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial